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Contribution of endothelin receptors in renal microvessels in acute
cyclosporine-mediated vasoconstriction in rats. Cyclosporine A (CsA), a
widely used immunosuppressive agent, causes renal vasoconstriction and
systemic hypertension. Recent data suggest that the renal effect of CsA is
possibly mediated by endothelin (ET). We investigated the effects of CsA
on renal microvessels and the efficacy of ETA or ETA/ETB receptor
antagonists in ameliorating CsA effects in the hydronephrotic rat kidney.
Infusion of CsA (30 mg z kg21) induced a transient increase (20%) in mean
arterial pressure (MAP) and a sustained reduction (85%) in glomerular
blood flow (GBF) due to preferential constriction of the arcuate artery
(39%) and the proximal segment of the interlobular artery (23%). Under
basal conditions the ETA receptor antagonist BQ-123 had marginal effects
consisting of reduction in MAP, rise in GBF and dilation of preglomerular
vessels. The non-selective ETA/ETB receptor antagonist PD 145065 also
reduced MAP, but tended to decrease GBF and constrict large preglo-
merular vessels. The difference in effects of the two antagonists indicated
that under basal conditions ETB blockade constricts large preglomerular
vessels and reduces GBF. After BQ-123 or PD 145065, the constriction of
large preglomerular vessels and reduction in GBF induced by CsA was
attenuated by about 50%, but the rise in MAP was not influenced. Our
data indicate that a sizable part of renal vasoconstriction due to CsA is
mediated via ET production in large preglomerular arteries and can be
avoided by the blockade of ETA receptors. Additional blockade of ETB
receptors does not attenuate the CsA effects further, possibly because
ETB receptors mediate both vasoconstriction and dilation.
Cyclosporine A (CsA) is commonly used for suppression of
graft rejection following organ transplantation and in the treat-
ment of some autoimmune diseases. Unfortunately, nephrotoxic-
ity and systemic hypertension remain the most important side
effects undermining the successful clinical use of this drug. The
initiating event in CsA nephrotoxicity is an intense renal vasocon-
striction. However, the underlying mechanisms for the CsA-
induced vasoconstriction are not yet entirely clear. Different
mechanisms have been suggested to be involved in this effect,
including activation of the sympathetic nervous system [1], eleva-
tion of thromboxane synthesis [2] and reduced production of
prostaglandins or endothelium-dependent vasodilators [3]. The
possibility that endothelin-1 (ET-1) may be involved in CsA-
induced nephrotoxicity has emerged only recently.
Endothelin-1 is an isopeptide of the ET family with potent
vasoconstrictor and vasopressor actions. In the kidney, ET-1
constricts renal microvessels, resulting in a fall in renal blood flow
and glomerular filtration rate [4, 5]. At least two types of receptors
(ETA and ETB) mediate the physiological effects of ET. The ETA
receptors, located on vascular smooth muscle cells, bind prefer-
entially to the isopeptide ET-1 and mediate the vasoconstrictor
and pressor response to ET-1 [6]. The ETB receptors, initially
discovered in endothelial cells, stimulate the release of nitric
oxide and prostaglandins in these cells and cause vasodilation.
However, ETB receptors are now recognized also to be present on
vascular smooth muscle cells, where they induce vasoconstriction.
Thus, ETB receptors can exert the dual effects of vasodilation and
vasoconstriction [4, 5]. In the kidney they have been recently
shown to induce vasodilation during basal conditions [7] and
vasoconstriction during application of exogenous ET-1 [8, 9].
Recent studies have demonstrated that CsA stimulates ET-1
release from cultured endothelial cells [10] and vascular smooth
muscle cells [11]. Increased urinary ET levels have been found in
CsA-treated animals [12, 13] and transplanted patients [14]. An
increase in circulating ET-1 levels has also been detected after
CsA treatment in humans [15] and in rats [16]. Furthermore, it
has been shown that acute renal vasoconstriction in response to
CsA is partially inhibited by ET-antibodies [16, 17]. New ET
receptor antagonists have now been developed, including non-
peptide antagonists suitable for therapeutic use, either selective
for ETA or non-selective for ETA/ETB [18], which might be used
beneficially during CsA treatment. However, the protective ef-
fects of different antagonists on CsA-induced renal vasoconstric-
tion have not yet been systematically investigated in animal experi-
ments. The few studies done with ETA [17, 19–21] or ETA/ETB
antagonists [22] do suggest a beneficial effect of these agents. The
only study in which both ETA and ETA/ETB antagonists were
tested [23], however, failed to find any ameliorating effects.
The aim of our study was to evaluate the role of ETA and ETB
receptors in CsA-induced changes in renal blood flow at a micro-
vascular level. As a model we used the hydronephrotic rat kidney,
in which almost all segments of the renal vascular tree are acces-
sible to measurements [24]. The validity of the hydronephrotic
kidney for renal microcirculation has been well established by
comparing the results obtained in this model with those obtained
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by other approaches for a variety of vasoactive agents [25]. The
interaction between CsA and ET receptors was investigated by
comparing the effects of CsA on renal microcirculation before
and after treatment, either with the ETA antagonist BQ-123 or
with the ETA and ETB antagonist PD 145065.
METHODS
Preparation of the hydronephrotic kidney
The experiments were performed on 18 female Wistar rats,
weighing 210 to 240 g in accordance with national animal protec-
tion guidelines. The technique and experimental procedures have
been previously described in detail [24, 26]. Unilateral surgical
hydronephrosis was induced by permanently ligating the left
ureter during pentobarbital sodium anesthesia (Nembutal®, 60
mg z kg21 i.p.; Ceva, Bad Segeberg, Germany). Two to three
months later the experiments were conducted under thiobutabar-
bital anesthesia (Inactin®, 100 mg z kg21 i.p.; BYK Gulden,
Konstanz, Germany). The rats were placed on a heated operating
table to maintain rectal temperature at 37°C. The trachea was
intubated and the left jugular vein was cannulated for the
continuous infusion of isotonic saline (50 ml z min21) and for
infusion of drugs. A polyethylene catheter was inserted into the
left femoral artery for continuous measurement of systemic blood
pressure. The left hydronephrotic kidney was exposed by a flank
incision and split along the great curvature using a thermal
cautery. The dorsal half of the split kidney was sutured to a
semicircular-shaped wire frame and fixed to the bottom of a
Plexiglas chamber for intravital transillumination microscopy. The
entry of the renal hilus into the chamber was sealed with silicon
grease and the chamber was filled with 50 ml of an isotonic,
isocolloidal solution (Haemaccel®; Behringwerke, Marburg/Lahn,
Germany) maintained at 37°C with a feedback-controlled heating
system. The table was then mounted on the microscope stage;
images of microvessels obtained through a water-immersion ob-
jective (Leitz Ultropack, UO-55) were displayed on a calibrated
monitor by a closed-circuit television system and recorded on
videotape. The kidney preparation was allowed to equilibrate in
the tissue bath for one hour before starting the experiments, and
the stability of the preparation was tested by repeating two
measurements of hemodynamic parameters at an interval of 15
minutes. The stability of the preparations had been demonstrated
for a duration of three hours [27].
Renal vascular segments
Vessels were identified according to their branching pattern
from a selected glomerulus. Lumen diameters of the following
segments were measured: (1) proximal arcuate artery (near the
interlobar artery); (2) distal arcuate artery; (3) proximal interlob-
ular artery (near the arcuate artery); (4) distal interlobular artery;
(5) proximal afferent arteriole (near the interlobular artery); (6)
distal afferent arteriole (within 100 mm from the glomerulus); (7)
proximal efferent arteriole (within 50 mm from the glomerulus);
(8) distal efferent arteriole (near the branching point of peritu-
bular capillaries).
Glomerular blood flow
Velocity of red blood cells was measured in the efferent
arteriole of the selected glomerulus by a velocity tracking corre-
lator (Model 102B; IPM Inc., San Diego, CA, USA) [28]. In order
to obtain glomerular blood flow (GBF), the measured red cell
velocity was multiplied by the luminal cross-section of the efferent
arteriole and corrected for the Fahreus-Lindqvist effect [29].
Experimental protocols
Each protocol consisted of 11 periods of 20 minutes each, at the
end of which mean arterial pressure (MAP), GBF and vascular
diameters were measured. The first period served as control.
During the next two periods CsA vehicle was infused either alone,
or additionally one of the peptide ET antagonists was first added
to the tissue bath (period 2), and then given i.v. (period 3). Period
3 served as control for subsequent interventions. Thereafter
(period 4 and 5) CsA (Sandimmune®; 30 mg z kg21; Sandoz
Pharmaceutical Co., Basel, Switzerland) dissolved in cremophor
EL, ethanol and physiological saline (final volume 2 ml) was
infused i.v. over 40 minutes and measurements were continued for
a follow-up time of 120 minutes (periods 6 to 11). Three series of
experiments were done. In group 1 (N 5 5) only the CsA vehicle
was administered during pre-treatment periods 2 and 3. In group
2 (N 5 6) ETA receptors were blocked by BQ-123 (Alexis
Deutschland, Germany) first by topical application in the tissue
bath (1026 M) and then in the third period by i.v. infusion (0.5 mg
z kg21). In group 3 (N 5 7) ETA/ETB receptors were blocked by
the non-selective antagonist PD 145065 (Parke Davis, Ann Arbor,
MI, USA) first by topical application (1025 M), then by i.v.
infusion (10 mg z kg21).
Statistical analysis
The data are presented as mean 6 SEM. Changes in vascular
diameters and GBF are expressed as percentage changes of the
preceding control value. Paired or unpaired t-test, ANOVA and
the Bonferroni method for multiple comparisons were used to test
statistical significance. The overall significance level was set to P ,
0.05.
RESULTS
Absolute values of the measured parameters in the three
experimental groups under control conditions (period 1) and after
vehicle or antagonist treatment (period 3) are shown in Table 1.
In group 1, CsA vehicle had no effect on the measured parame-
ters.
Effects of endothelin receptor antagonists
In group 2 topical application of the ETA antagonist BQ-123 to
the kidney dilated predominantly preglomerular vessels and in-
creased GBF (19 6 9%, NS) without affecting MAP. The
subsequent i.v. infusion of BQ-123 decreased MAP without any
further effect on renal vessels and GBF (17 6 10% above
control). Relative changes in the measured parameters after i.v.
infusion are depicted in Figure 1. In group 3 topical application of
ETA/ETB antagonist PD 145065 dilated small preglomerular
vessels (distal interlobular arteries and afferent arterioles, P ,
0.05), constricted upstream arterioles non-significantly and did
not affect GBF or MAP (data not shown). The subsequent i.v.
infusion of PD 145065 reduced MAP and GBF, whereas the
dilation of small preglomerular arterioles was marginally attenu-
ated and constriction of upstream vessels enhanced (Fig. 1). The
difference between PD 145065 and BQ-123 effects, which corre-
sponded to the effect of ETB receptor blockade, showed a
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constriction of preglomerular vessel segments and a reduction in
GBF.
Effects of cyclosporine A
The relative changes in MAP and GBF in control and pre-
treated animals due to CsA infusion for 40 minutes and after
the follow-up time of 120 minutes versus pre-infusion values
are shown in Figure 2. In control rats MAP increased to its
peak value within the first 20 minutes of the infusion to
decrease slowly with time and to return to control value 20
minutes after stopping the infusion. On the other hand, GBF
decreased gradually during the infusion to a nadir value 85%
below control and did not recover substantially during the
follow up time of 120 minutes. The relative changes in the
luminal diameters of renal vessels at the end of CsA infusion
and at the end of the follow-up are shown in Figure 3. In
control rats, CsA constricted large preglomerular vessel seg-
ments (proximal interlobular artery and upstream segments).
Among the postglomerular segments, the distal efferent arte-
riole also constricted, but the change in this segment with
scanty smooth muscles was likely to be of passive nature. The
constriction of large preglomerular vessels was more pro-
nounced at the end of CsA infusion than at the end of the
follow up time, indicating some recovery at the vascular level.
Table 1. Absolute values of luminal diameter and other parameters under control conditions and at the end of the initiating treatment are given as
mean 6 SEM (see text for details)
Group 1 Group 2 Group 3
Baseline Vehicle Baseline BQ-123 Baseline PD 145065
Arcuate artery, proximal m 57.8 6 4.0 57.9 6 2.8 47.7 6 3.3 54.3 6 4.2a 55.9 6 4.7 52.1 6 4.1a
Arcuate artery, distal m 44.4 6 1.7 44.4 6 2.4 40.2 6 3.1 42.9 6 4.2a 42.7 6 3.3 39.5 6 2.7
Interlobular artery, proximal m 27.8 6 2.8 29.2 6 2.6a 24.4 6 1.1 27.9 6 0.8a 24.9 6 1.6 24.3 6 1.8
Interlobular artery, distal m 16.0 6 1.1 16.9 6 0.8 12.6 6 1.3 14.8 6 1.5a 15.8 6 1.5 16.6 6 1.4
Afferent arteriole, proximal m 11.8 6 0.4 12.1 6 0.6 11.2 6 0.7 13.0 6 0.8 10.2 6 0.5 11.0 6 0.5
Afferent arteriole, distal m 9.6 6 0.8 9.4 6 0.8 9.2 6 1.0 11.3 6 0.7a 8.4 6 0.3 8.9 6 0.3a
Efferent arteriole, proximal m 12.0 6 1.4 12.9 6 1.6 9.3 6 0.9 10.5 6 0.4 10.5 6 0.7 11.4 6 1.0
Efferent arteriole, distal m 15.2 6 1.1 15.8 6 0.8 14.4 6 1.0 15.9 6 1.2 16.2 6 0.5 16.0 6 1.3
Glomerular blood flow (GBF) nl/min 61.5 6 14.1 61.2 6 17.7 59.8 6 5.7 68.1 6 4.6 64.5 6 11.2 57.8 6 13.8
Blood pressure (MAP) mm Hg 114.0 6 4.3 117.0 6 4.1 112.5 6 2.1 108.3 6 2.8a 117.1 6 3.1 111.4 6 5.1a
Body weight g 220 6 8 219 6 4 235 6 6
a P , 0.05 vs. control.
Fig. 1. Percentage changes in renal vascular
diameter, glomerular blood flow (GBF) and
mean arterial pressure (MAP) at the end of i.v.
infusion of BQ-123 (o) or PD 145065 (M).
Vessel segments starting from the proximal
arcuate artery to the distal efferent arteriole are
numbered 1 to 8 (Methods). The break
represents the glomerulus. #P , 0.05 versus
control, *P , 0.05 PD 145065 versus BQ-123.
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Modulation of cyclosporine A’s effects by endothelin
antagonists
As shown in Figure 2, in the rats pretreated with BQ-123 or PD
145065, CsA infusion caused a marked increase in MAP compa-
rable to that in control animals (16.3 6 2.2% or 15.8 6 5.1%,
respectively, vs. 20.7 6 3.2% in control). The pattern of MAP
changes with time was similar in the three groups. Glomerular
blood flow also decreased gradually during CsA infusion and
remained low during the postinfusion period, but the maximal
change was distinctly less in pretreated groups than in the control
group (252 6 3% for BQ-123 and 236 6 9% for PD 145065 vs.
285 6 5% in controls). Though the reduction in GBF after PD
145065 was less than after BQ-123, the difference was not
significant. The constriction of large vessels due to CsA, respon-
sible for the reduction in GBF, was also attenuated by both ET
antagonists (Fig. 3), but no distinct difference could be observed
between the two agents at microvascular level.
DISCUSSION
Cyclosporine A (CsA) infusion evokes an acute systemic hyper-
tension and causes a significant reduction in renal blood flow and
glomerular filtration rate in humans as well as in experimental
animals due to an increase in renal vascular resistance [30, 31]. A
number of studies indicate that endogenous endothelin (ET), a
paracrine hormone, plays a substantial role in the renal vasocon-
strictor effect of CsA [16, 17, 19–22, 32]. How much of this effect
is mediated via ETA or ETB or by both receptors has, however,
not been investigated in detail.
In the present study we first investigated the effects of ET
receptor blockade on renal microcirculation and systemic blood
pressure. The efficacy of the dose of the ETA antagonist BQ-123
or the ETA/ETB antagonist PD 145065 used in this study had been
tested earlier [7, 8]. We were able to show that ETA receptors
exert a vasoconstrictor action in the kidney under basal condi-
tions. In our experiments, BQ-123 dilated most of the preglo-
merular vessels. On the other hand, PD 145065 had little effect on
microcirculatory parameters. However, PD 145065 data, when
compared with those of BQ-123 (Fig. 1), revealed that blockade of
ETB receptors caused a distinct constriction of preglomerular
vessels and a reduction in GBF. Thus, under basal conditions
endogenous ET dilates preglomerular vessels via stimulation of
ETB receptors, but a part of this vasodilation is counterbalanced
by concomitant stimulation of ETA receptors in the same vascular
segments. The reduction in blood flow due to PD 145065 was not
significant compared to control in these experiments, but attained
a significant level in a recent study on normal filtering kidneys [7].
Since the fall in MAP due to BQ-123 and PD 145065 was similar,
the constrictor effect of ETA seems to dominate over the dilator
effect of ETB in the systemic circulation, which has also been
shown by others [5]. In a previous study on the hydronephrotic
kidney, it was shown that at high concentrations exogenous ET-1
causes renal vasoconstriction via both receptor subtypes, and that
Fig. 2. Time course of changes in mean
arterial pressure (MAP) and glomerular blood
flow (GBF) due to cyclosporine A (CsA)
infusion and during postinfusion periods in the
three experimental groups. Pretreatments were:
vehicle (F), BQ-123 (M) and PD 145065 ().
#P , 0.05 versus baseline, *P , 0.05 versus
vehicle group. In A, # is valid for all groups.
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ETA constricts only preglomerular vessels whereas ETB constricts
both pre- and postglomerular vessels [8]. These data suggest that
ETA causes preglomerular vasoconstriction independent of ET-1
concentration, whereas ETB dilates preglomerular vessels at low
basal concentrations of ET-1 and constricts pre- and postglomeru-
lar ones at higher concentrations. Preglomerular vasodilation by
ETB receptors under basal conditions has also been demonstrated
by micropuncture technique [33].
In our study, CsA markedly decreased GBF and this effect was
related to a sustained constriction of the large preglomerular
vessels, the arcuate artery and proximal interlobular artery. A
reduction in diameter of distal efferent arterioles, also found in
our experiments, should be rather attributed to a passive response
of this vessel segment with scanty smooth muscles to a reduction
in its perfusion pressure, secondary to preglomerular vasocon-
striction. A similar pattern of diameter changes due to CsA in the
hydronephrotic kidney was also observed in an earlier study [34].
Circumstantial evidence for CsA-induced constriction of large
preglomerular vessels can also be derived from the findings that in
this and previous studies on the hydronephrotic kidney [17, 34]
CsA reduced GBF by about 80%, whereas in normal kidneys the
reduction in renal blood flow due to a comparable dose was half
as much [16, 19–23]. This difference may be related to the finding
that the large preglomerular vessels contribute twice as much to
the total renal resistance in the hydronephrotic kidney than in the
normal kidney [35]. Preglomerular vasoconstriction due to CsA
has been shown by Kon et al [16], who measured a reduction in
glomerular capillary pressure due to increased preglomerular
vascular resistance. In contrast to our findings Bloom, Bentley and
Garrison [17], who investigated the effects of CsA on the inter-
lobular artery, afferent arteriole and efferent arteriole of the
hydronephrotic kidney, observed a similar reduction in diameter
for each of these vessels. However, they used a very high
concentration of CsA in tissue bath (2.6 z 1022 mol z liter21 vs. 2.5
z 1025 mol z kg21 body wt i.v. in our experiments), and hence it is
conceivable that at higher concentrations of CsA small arterioles
are also recruited in the constriction. Lanese and Conger [32],
using isolated perfused afferent or efferent arterioles, found a
CsA (10211 mol z liter21) induced vasoconstriction in both
microvessels. The reason for this discrepancy remains unclear.
Fig. 3. Changes in vascular diameters due to
cyclosporine A (CsA) in animals pretreated
with vehicle (f), with BQ-123 (o) and with PD
145065 (M). The upper panel shows values at
the end of CsA infusion for 40 minutes and
lower panel values at the end of postinfusion
periods at 160 minutes. #P , 0.05 versus
baseline, *P , 0.05 vs. vehicle group.
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Previous studies have suggested that CsA stimulates synthesis
of the paracrine hormone ET-1 preferentially in the kidney.
Cyclosporine A has been shown to increase urinary excretion of
ET-1 from undetectable levels to high values [12, 13], whereas
plasma ET-1 has been reported to remain unchanged [13] or to
increase either marginally [15] or substantially [16]. Considering
further that CsA has been shown to increase synthesis of ET-1 in
cultured endothelial [10] and smooth muscle cells [11], it seems
likely that ET-1 synthesis in the kidney occurs in blood vessels.
Furthermore, expression of ET-1 mRNA was found to be in-
creased after CsA treatment selectively in the renal medullary
tissue [13], where the large preglomerular vessels are situated.
The major difference between the effects of exogenous ET-1,
mimicking a humoral rise, determined in a previous study [8] and
of CsA in this study was that ET-1 constricted not only large
preglomerular vessels but also the distal interlobular artery and
afferent and efferent arterioles, whereas CsA had no effect on
these small vessels. Thus, CsA should have induced production of
ET-1 only in large vessels situated within or lining the renal
medulla and constricted them in paracrine fashion.
Pretreatment with ETA or ETA/ETB antagonists in our study
attenuated CsA-induced reduction in GBF to half of that in
untreated animals. Though the recovery of GBF after application
of ETA/ETB antagonist was more pronounced than after ETA
antagonist, the difference was not significant. The ameliorating
effect of the antagonists was related to the attenuation of CsA
dependent constriction in the arcuate artery and the proximal
interlobular artery. Again, no significant difference in vessel
diameters could be discerned between the two antagonists. These
findings indicate that a substantial part of renal vasoconstriction
due to CsA occurs via ET release and stimulation of ETA
receptors in the large preglomerular vessels. The expected con-
comitant stimulation of ETB receptors appears to play a minor
role and may be related to its dual mode of action, namely
vasodilation and vasoconstriction. Furthermore, it has been
shown that on one hand stimulation of ETB receptors can enhance
clearance of circulating ET-1 [36] but at the same time it may
stimulate production of ET-1 [37].
As to the effect of ET receptor antagonists on CsA-induced
renal vasoconstriction, the data obtained from rats are conflicting.
Fogo et al [19], using the clearance technique for measuring renal
plasma flow, could attenuate CsA effects in the left kidney by
infusing BQ-123 into the left renal artery, but found no protective
effect of systemically infused BQ-123. Kivlighn, Gabel and Siegl
[20], using the same technique, also reported a protective effect of
BQ-123 pretreatment; however, they infused the antagonist sys-
temically. The above studies do not permit a determination of
whether the antagonism between CsA and BQ-123 was complete
or only partial. The renal plasma flow in both studies was lower
after CsA in the pretreated animals, but the difference in values
before and after CsA was not statistically significant. Using an
electromagnetic flowmeter, Conger, Kim and Robinette [21]
found that BQ-123 inhibited CsA-induced reduction in renal
blood flow completely, but the corresponding rise in renal vascu-
lar resistance only partially. Davis et al [23], who used a transit
time flow probe, failed to see any antagonism between CsA and
BQ-123 in the kidney. In the hydronephrotic kidney [17] the
constriction of the interlobular artery, afferent arteriole and
efferent arteriole due to CsA in the tissue bath was attenuated by
an ETA antagonist (PED-3512-PI), whereas in experiments with
isolated perfused arterioles BQ-123 inhibited CsA-induced vaso-
constriction only in the afferent but not in the efferent arteriole
[32]. In two studies, the effect of CsA was challenged by nonse-
lective ETA/ETB antagonists. In one study, using the clearance
technique [22], (6)-SB 209670 attenuated renal vasoconstriction
due to CsA, whereas in the other study using the transit time flow
probe [23] PD 142893 was ineffective. In contrast to renal effects,
the transient rise in MAP was not influenced by either antagonist.
Similar data have been reported for BQ-123 [21] and an ETA/ETB
antagonist [23]. Thus, the systemic effects of CsA do not seem to
be primarily related to ET.
In conclusion, our data show that a substantial part of CsA-
induced renal vasoconstriction is related to ET and stimulation of
ETA receptors in large preglomerular vessels. The likely stimula-
tion of ETB receptors seems to play a subordinate role due to
their dual mode of action. Unlike ETA receptors, which always
mediate a vasoconstriction, ETB can also dilate renal vessels, at
least under control conditions. Whether further subtypes of ETB
receptors are responsible for this dual action remains to be
clarified. Further studies are needed to clarify whether chronic
ETA receptor blockade can significantly attenuate nephrotoxicity
of CsA.
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